Annual CFF
$137.55 M
+$89.24 M+184.71%
31 December 2023
Summary:
Sutro Biopharma annual cash flow from financing activities is currently $137.55 million, with the most recent change of +$89.24 million (+184.71%) on 31 December 2023. During the last 3 years, it has risen by +$134.30 million (+4124.63%). STRO annual CFF is now -48.91% below its all-time high of $269.25 million, reached on 31 December 2020.STRO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.02 M
-$95.47 M-98.95%
30 September 2024
Summary:
Sutro Biopharma quarterly cash flow from financing activities is currently $1.02 million, with the most recent change of -$95.47 million (-98.95%) on 30 September 2024. Over the past year, it has increased by +$4.14 million (+132.54%). STRO quarterly CFF is now -99.30% below its all-time high of $144.85 million, reached on 31 December 2020.STRO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$90.95 M
+$6.76 M+8.03%
30 September 2024
Summary:
Sutro Biopharma TTM cash flow from financing activities is currently $90.95 million, with the most recent change of +$6.76 million (+8.03%) on 30 September 2024. Over the past year, it has dropped by -$46.60 million (-33.88%). STRO TTM CFF is now -66.22% below its all-time high of $269.25 million, reached on 31 December 2020.STRO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
STRO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +132.5% | -33.9% |
| 3 y3 years | +4124.6% | +101.0% | +2693.4% |
| 5 y5 years | +3387.6% | +157.1% | +2273.8% |
STRO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +4124.6% | -99.3% | +117.7% | -51.8% | +4053.1% |
| 5 y | 5 years | -48.9% | +3387.6% | -99.3% | +117.7% | -66.2% | +2273.8% |
| alltime | all time | -48.9% | +3387.6% | -99.3% | +117.7% | -66.2% | +2273.8% |
Sutro Biopharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.02 M(-98.9%) | $90.95 M(+8.0%) |
| June 2024 | - | $96.49 M(-2913.9%) | $84.20 M(-32.8%) |
| Mar 2024 | - | -$3.43 M(+9.7%) | $125.37 M(-8.9%) |
| Dec 2023 | $137.55 M(+184.7%) | -$3.13 M(-45.6%) | $137.55 M(-10.0%) |
| Sept 2023 | - | -$5.74 M(-104.2%) | $152.90 M(-18.9%) |
| June 2023 | - | $137.66 M(+1471.8%) | $188.49 M(+234.7%) |
| Mar 2023 | - | $8.76 M(-28.3%) | $56.31 M(+16.6%) |
| Dec 2022 | $48.31 M(+1383.8%) | $12.22 M(-59.1%) | $48.31 M(+32.0%) |
| Sept 2022 | - | $29.85 M(+444.2%) | $36.60 M(+374.4%) |
| June 2022 | - | $5.49 M(+621.7%) | $7.71 M(+252.2%) |
| Mar 2022 | - | $760.00 K(+50.2%) | $2.19 M(-32.7%) |
| Dec 2021 | $3.26 M | $506.00 K(-47.5%) | $3.26 M(-97.8%) |
| Sept 2021 | - | $963.00 K(-2569.2%) | $147.60 M(-9.9%) |
| June 2021 | - | -$39.00 K(-102.1%) | $163.91 M(-35.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $1.83 M(-98.7%) | $255.37 M(-5.2%) |
| Dec 2020 | $269.25 M(-6535.2%) | $144.85 M(+738.7%) | $269.25 M(+119.6%) |
| Sept 2020 | - | $17.27 M(-81.1%) | $122.61 M(+17.7%) |
| June 2020 | - | $91.42 M(+482.2%) | $104.21 M(+770.2%) |
| Mar 2020 | - | $15.70 M(-982.1%) | $11.98 M(-386.2%) |
| Dec 2019 | -$4.18 M(-102.4%) | -$1.78 M(+57.9%) | -$4.18 M(-104.9%) |
| Sept 2019 | - | -$1.13 M(+37.6%) | $85.45 M(-37.5%) |
| June 2019 | - | -$819.00 K(+78.8%) | $136.75 M(-19.7%) |
| Mar 2019 | - | -$458.00 K(-100.5%) | $170.34 M(-0.3%) |
| Dec 2018 | $170.78 M(+1066.7%) | $87.86 M(+75.1%) | $170.78 M(+105.9%) |
| Sept 2018 | - | $50.17 M(+53.1%) | $82.93 M(+153.2%) |
| June 2018 | - | $32.77 M(<-9900.0%) | $32.76 M(<-9900.0%) |
| Mar 2018 | - | -$14.00 K | -$14.00 K |
| Dec 2017 | $14.64 M(+8170.1%) | - | - |
| Dec 2016 | $177.00 K | - | - |
FAQ
- What is Sutro Biopharma annual cash flow from financing activities?
- What is the all time high annual CFF for Sutro Biopharma?
- What is Sutro Biopharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sutro Biopharma?
- What is Sutro Biopharma quarterly CFF year-on-year change?
- What is Sutro Biopharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sutro Biopharma?
- What is Sutro Biopharma TTM CFF year-on-year change?
What is Sutro Biopharma annual cash flow from financing activities?
The current annual CFF of STRO is $137.55 M
What is the all time high annual CFF for Sutro Biopharma?
Sutro Biopharma all-time high annual cash flow from financing activities is $269.25 M
What is Sutro Biopharma quarterly cash flow from financing activities?
The current quarterly CFF of STRO is $1.02 M
What is the all time high quarterly CFF for Sutro Biopharma?
Sutro Biopharma all-time high quarterly cash flow from financing activities is $144.85 M
What is Sutro Biopharma quarterly CFF year-on-year change?
Over the past year, STRO quarterly cash flow from financing activities has changed by +$4.14 M (+132.54%)
What is Sutro Biopharma TTM cash flow from financing activities?
The current TTM CFF of STRO is $90.95 M
What is the all time high TTM CFF for Sutro Biopharma?
Sutro Biopharma all-time high TTM cash flow from financing activities is $269.25 M
What is Sutro Biopharma TTM CFF year-on-year change?
Over the past year, STRO TTM cash flow from financing activities has changed by -$46.60 M (-33.88%)